For research use only. Not for therapeutic Use.
BCI-215（Cat No.:I017415）is a small molecule inhibitor of SHP2 (Src homology region 2-containing protein tyrosine phosphatase-2), a key enzyme involved in cell signaling pathways that regulate proliferation, differentiation, and survival. SHP2 plays an important role in the RAS/MAPK pathway, which is often dysregulated in cancer. By inhibiting SHP2, BCI-215 effectively disrupts oncogenic signaling, reducing tumor cell growth and survival. It is particularly useful in cancer research, exploring therapeutic strategies for tumors driven by aberrant SHP2 or RAS/MAPK signaling. BCI-215 also offers potential applications in developmental disorders associated with SHP2 mutations.
| Catalog Number | I017415 |
| CAS Number | 1245792-67-9 |
| Molecular Formula | C₂₂H₂₂BrNO |
| Purity | ≥95% |
| IUPAC Name | (2E)-2-benzylidene-5-bromo-3-(cyclohexylamino)-3H-inden-1-one |
| InChI | InChI=1S/C22H22BrNO/c23-16-11-12-18-19(14-16)21(24-17-9-5-2-6-10-17)20(22(18)25)13-15-7-3-1-4-8-15/h1,3-4,7-8,11-14,17,21,24H,2,5-6,9-10H2/b20-13+ |
| InChIKey | JGWQWVVSCQBAFC-DEDYPNTBSA-N |
| SMILES | C1CCC(CC1)NC\2C3=C(C=CC(=C3)Br)C(=O)/C2=C/C4=CC=CC=C4 |
| Reference | [1]. Korotchenko VN, et al. In vivo structure-activity relationship studies support allosteric targeting of a dual specificity phosphatase. Chembiochem. 2014 Jul 7;15(10):1436-45.<br>[2]. Kaltenmeier CT, et al. A Tumor Cell-Selective Inhibitor of Mitogen-Activated Protein Kinase Phosphatases Sensitizes Breast Cancer Cells to Lymphokine-Activated Killer Cell Activity. J Pharmacol Exp Ther. 2017 Apr;361(1):39-50. |
